Is Ascletis Pharma Inc. (ASCLF) a Buy, Sell, or Hold?
OTC : ASCLF
Ascletis Pharma Inc.
$1.42 USD
$0 (0.0%)
- Volume
- 225
- Average Volume
- 516
- Market Capitalization
- $1.49B
- P/E Ratio
- -20.97
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.50
- Year Low
- $1.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.05
Company Overview
OTC
Jinzi J. Wu
Biotechnology
Healthcare
ASCLF
202
CN
USD
Liquidity Metrics
0.00
15.05
15.04
11.31
0.00
Sales & Valuation
$1.98M
4035.57
3.96
-21.55
-0.39
Profitability
-$0.36
-$350.59M
-17745.56%
-17720.61%
-18.93%
-17.41%
P/E Metrics
-20.97
0.61
0.61
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
45.05
1/9
$1.79B
$2.07B
$129.94M
-$883.88M
Key Metrics (TTM)
$6.74B
3323.68
-14.29
15.05
-18.93%
-24.90%
-4.70%
-4.64%
2509 days
Company Executives
| Name | Title |
|---|---|
| George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor |
| Jinzi Wu | Founder, Chairman & Chief Executive Officer |
| Hejingdao Wu | Senior Vice President of Operations & Executive Director |
| Ming Fai Chung | Company Secretary |
| John Gargiulo | Chief Business Officer |
| Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery |
Poll Results
No votes yet today — be the first to share your view!
About Ascletis Pharma Inc. (OTC:ASCLF) Stock
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based ... in Hangzhou, the People's Republic of China.
2026-06-23 06:10:00
Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized tirzepatide once-weekly formulation.
2026-06-07 20:10:00
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portfolio in obesity treatment, including small-molecule candidates, a peptide therapeutic, and an oral peptide delivery-enhancing technology. The data attracted considerable interest from leading experts at the meeting and further underscored Ascletis' innovation capabilities in metabolic disease therapeutics.
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
2026-05-05 20:10:00
HONG KONG, May 5, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on the Phase I data of ASC47, an adipose-targeting thyroid hormone receptor beta (THRβ) agonist for muscle-preserving weight loss, which, in combination with semaglutide, demonstrated up to 111.8% greater relative weight loss in participants with obesity compared to semaglutide monotherapy, and a poster on the preclinical data of ASC36, a once-monthly next-generation amylin receptor agonist peptide, which demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in non-human primate (NHP) model and 91% more relative weight loss than petrelintide in diet-induced obese (DIO) rat model.
2026-04-29 20:10:00
HONG KONG, April 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA's) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of ASC39, an eloralintide-like selective and potent oral small molecule amylin receptor agonist for the treatment of obesity.
2026-04-26 20:10:00
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third quarter of 2026.
Frequently Asked Questions
-
What is the current Ascletis Pharma Inc. (ASCLF) stock price?
-
Ascletis Pharma Inc.(OTC:ASCLF) stock price is $1.42 in the last trading session. During the trading session, ASCLF stock reached the peak price of $2.5 while $1.145 was the lowest point it dropped to. The percentage change in ASCLF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ASCLF stock was $0.
-
ASCLF's industry and sector of operation?
-
The OTC listed ASCLF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ASCLF?
-
George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor
Jinzi Wu | Founder, Chairman & Chief Executive Officer
Hejingdao Wu | Senior Vice President of Operations & Executive Director
Ming Fai Chung | Company Secretary
John Gargiulo | Chief Business Officer -
How many employees does ASCLF have?
-
Number of ASCLF employees currently stands at 202. ASCLF operates from 12/F, Building D, Hangzhou, ENG 311200, CN.
-
Link for ASCLF official website?
-
Official Website of ASCLF is: https://www.ascletis.com
-
How do I contact ASCLF?
-
ASCLF could be contacted at phone #86 571 8538 9730 and can also be accessed through its website. ASCLF operates from 12/F, Building D, Hangzhou, ENG 311200, CN.
-
How many shares of ASCLF are traded daily?
-
The average number of ASCLF shares traded daily for last 3 months was 516.
-
What is the market cap of ASCLF currently?
-
The market value of ASCLF currently stands at $1.49B with its latest stock price at $1.42